RELIEF THERAPEUTICS Holding AG (OTCQB: RLFTF) plunged down -39.84 to 0.379 at yesterday’s close. The Company Volume was 104.26M in contrast with its Average Weekly volume of 31.20M.
What they do?
Relief Therapeutics Holding AG is a Swiss drug development company specializing in clinical stage drugs, primarily developing products of natural human origin. This company is focused on developing pharmaceutical products for diabetic complications and respiratory diseases, including Aviptadil and Atexakin alfa.
Thomaz Burckhardt, the member of the RELIEF THERAPEUTICS Holding AG’s Board of Directors, has resigned effective immediately. Burckhardt has resigned to devote his time and effort to other duties and interests.
The Board of Directors and I would like to thank Thomaz for his many contributions to the Company throughout the years. We wish him well in his future endeavors, said Raghuram Selvaraju, Chairman of the Board of Relief.
Relief will evaluate candidates for the position of an independent director who has extensive experience in the life sciences/healthcare with respect to filling the current vacancy.
Relief will continually assess its options for growing its Board and Executive Management team. This will enable Relief to maximize its ability to execute its business strategy in the future.
Biotechnology is entering an era that some experts consider to be the golden age. A new era of medical science is enabling new ways to treat and prevent diseases previously unimaginable. Stocks in biotech offer investors the chance to make a killing during this period.